Table 2. Baseline patient characteristics.
| Characteristics | n |
|---|---|
| No. of evaluable patients | 155 |
| Gender | |
| Male | 89 (57.4%) |
| Female | 66 (42.6%) |
| Age (range), years | 65.8 ± 10.64 (27–87) |
| Weight (range), kg | 69.7 ± 14.76 (35–115) |
| Height (range), cm | 168.1 ± 8.90 (131–186) |
| Location of cancer | |
| Colorectal | 93 (60.0%) |
| Pancreas | 33 (21.3%) |
| Esophagus | 11 (7.0%) |
| Stomach | 10 (6.5%) |
| Others | 8 (5.2%) |
| Type of chemotherapy | |
| Metastatic | 128 (82.6%) |
| Adjuvant | 27 (17.4%) |
| Protocol of chemotherapy | |
| Simplified Folfox-6 | 61 (39.4%) |
| Folfirinox | 50 (32.3%) |
| Folfiri | 28 (18.1%) |
| LV5FU2 | 9 (5.7%) |
| Folfiri-3 | 7 (4.5%) |
| Biotherapy | |
| Yes | 74 (47.7%) |
| No | 81 (52.3%) |
| Line of treatment | |
| 1st line | 80 (51.6%) |
| 2nd line | 45 (29.0%) |
| 3rd line or more | 30 (19.4%) |